dabigatran has been researched along with Rectal Diseases in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Horn, EP; Langer, F; Mofid, H; Thorborg, C | 1 |
| Béné, J; Coupe, P; Deheul, S; Gautier, S; Rannou, M; Saïd, W | 1 |
2 other study(ies) available for dabigatran and Rectal Diseases
| Article | Year |
|---|---|
Reversal by the specific antidote, idarucizumab, of elevated dabigatran exposure in a patient with rectal perforation and paralytic ileus.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antidotes; Dabigatran; Female; Humans; Intestinal Perforation; Intestinal Pseudo-Obstruction; Rectal Diseases | 2016 |
Rectal bleeding and hemostatic disorders induced by dabigatran etexilate in 2 elderly patients.
Topics: Aged; Aged, 80 and over; Antithrombins; Benzimidazoles; Dabigatran; Female; Hemorrhage; Hemostatic Disorders; Humans; International Normalized Ratio; Male; Pyridines; Rectal Diseases | 2012 |